In 2013, Mylan became a global injectables leader with the acquisition of Agila Specialties. The transaction significantly expanded the company’s injectable manufacturing capabilities in India. Today, Mylan operates seven injectables facilities, five of which are based in India. The company offers a robust portfolio of high quality specialty and generic injectables in a variety of important therapeutic categories, such as oncology, anti-infective and cardiovascular. Mylan sells these products around the world including the Brazil, Canada, Europe, Japan and the U.S.

Our technological capabilities have been enhanced significantly with our industry-leading sterile manufacturing, state-of-the-art lyophilization process and diverse delivery systems, which include:

  • Lyophilized and liquid vials,
  • pre-filled syringes,
  • ampoules and
  • mini bags.

Mylan’s global injectables capacity is more than 500 million units. Moreover, Mylan’s lyophilization capacity is one of the largest in the world.